The probably consequence for JWH 018 is the fact that further more investigation will result in an more potent cannabinoid. In July 2016, MDMB-CHMICA was the very first artificial cannabinoid receptor agonist being risk-assessed via the EMCDDA (35) and it's got a short while ago been subj